Skip to main content
E

EMBioSys

EMBioSys develops wearable technology utilizing induced Electric Field (iEF) Therapy as a novel modality for cancer treatment. This science-backed approach offers patients an alternative to traditional surgery, pharmaceuticals, and ionizing radiation. The company focuses on creating gentler, next-generation oncological care solutions.

North Andover, United StatesFounded 20224100+ followers
Updated 4 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Triple-Negative Breast Cancer (TNBC) is a particularly aggressive form of breast cancer with limited treatment options, high recurrence rates, and a low five-year survival rate when metastasis occurs. Current treatments often have harsh side effects and may not effectively prevent the spread of the disease.

Solution

EMBioSys is developing non-invasive, electrode-free wearable garments that deliver therapeutic induced Electric Fields (iEF Therapy) to target and inhibit the metastasis of solid tumors, particularly TNBC. The iEF Therapy works by altering the cancer cell's cytoskeleton, metabolically depriving cells of energy, reversing epithelial-to-mesenchymal transition (EMT), and enhancing the immune response by attracting anti-tumor immune cells. This approach aims to improve treatment outcomes by reducing tumor volume and weight, enhancing the efficacy of chemotherapy, and selectively targeting cancer cells without adverse effects. The wearable garments are designed for patient use at home, providing a convenient and non-toxic method to potentiate the standard of care.

Target Audience

The primary target audience includes patients diagnosed with Triple-Negative Breast Cancer (TNBC) and their healthcare providers, specifically oncologists and hospitals specializing in breast cancer treatment.

Features

  • Non-pharmacological, non-toxic, electrode-free wearable garments for home use
  • Delivers therapeutic induced Electric Fields (iEF Therapy)
  • Alters cancer cell cytoskeleton, hindering movement
  • Metabolically deprives cancer cells of energy to move and proliferate
  • Reverses epithelial-to-mesenchymal transition (EMT) to prevent detachment
  • Enhances immune response by attracting anti-tumor immune cells
  • Reduces tumor volume and weight
  • Improves efficacy of chemotherapy
This profile is AI-generated and may contain inaccuracies.